Log in using OpenID

Dementia Drugs market

Dementia Drugs - Size, Share, Growth, Outlook,
and Opportunity Analysis, 2018-2026
Dementia is a form of disease that affects the functioning of the brain resulting in decline in memory
or other thinking skills. Alzheimer’s disease is the most common and largest form of dementia (in over
60% cases), which is observed among people aged 65 years and above. Accumulation of a protein
called beta amyloid, in the spaces between nerve cells due to genetic mutation is a major cause of
dementia. Although dementia disease is not treatable, symptomatic treatment is followed in all cases.
Research is being carried out to develop treatment centered on the role of beta-amyloid in dementia.
Request Sample Copy of Research Report:
Increasing number of pipeline products is expected to drive growth of the dementia
drugs market
Major factors fueling growth of the dementia drugs market include the large number of drugs in
the pipeline, which are expected to enter into the market by 2020-2022. According to the study
published by Translational Research and Clinical Intervention, in September 2017, it is recorded
that 105 new drugs in pipeline, out of which 25 are in phase one, 52 in phase two and 28 are in
phase three. These new products use novel approaches such as immunotherapy to target
amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation
inhibitor, and serotonin 5-HT6 receptor antagonist. Furthermore, increasing collaborations
amongst companies for developing drugs in joint efforts is also boosting growth of the market.
For instance, in November 2017, Novartis and Amgen, along with the Banner Alzheimer's
Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to prevent
or delay symptoms of Alzheimer's disease. However, failure of investigational candidate in late
stage is expected to be a huge setback in the current Alzheimer’s drugs market. For instance, in
February 2017, an external data monitoring committee warned that Merck & Co., Inc. terminated
study of Alzheimer's candidate verubecestat due to potential failure in a Phase II/III study.
Dementia Drugs Market Regional Outlook - Growing Integration of Healthcare and IT
to boost demand in emerging economies
On the basis of geography, the global dementia drugs market can be segmented into six major
regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North
America is expected to hold the largest market, owing to major approval of drugs in this region
and favorable reimbursement scenarios. Asia Pacific is expected to emerge as a major market in
the near future, majorly due to the growing geriatric population and Alzheimer’s disease cases,
especially in China, India. This in turn, is expected to create lucrative opportunities for growth of
the market. For instance, according to Alzheimer’s Disease International Association, in 2015,
East Asia is the region with the maximum number of people living with dementia (9.8 million),
followed by Western Europe (7.4 million).
Report includes chapters which deeply display the following deliverable about industry :
• Dementia Drugs Research Objective and Assumption
• Dementia Drugs Purview - Report Description, Executive Summary, and Coherent Opportunity Map
• Dementia Drugs Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory
Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain
Analysis, Porter’s Analysis, and PEST Analysis
• Global Dementia Drugs, By Regions
• Dementia Drugs Competition by Manufacturers including Production, Share, Revenue, Average
Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Dementia Drugs Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Dementia Drugs Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of
Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Dementia Drugs Forecast including Production, Consumption, Import and Export Forecast by Type,
Applications and Region.
• Research Findings and Conclusion
Some of the top companies operating in the dementia drugs market are Eisai, Inc.,
Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli
Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La
Roche, Merck & Co., Inc.., Valeant Pharmaceutical International, Pfizer Inc., and Teva
Pharmaceuticals Industries Ltd.
Inquire Here Before Purchase:
Detailed Segmentation:
• Global Dementia Drugs Market, By Drug Class:
• MAO Inhibitors
• Cholinesterase Inhibitors
• Glutamate Inhibitors
• Global Dementia Drugs Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Others
• Global Dementia Drugs Market, By Region:
• North America
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Rushikesh79   documents Email
Health and Medicine
File Size
157 KB
Report inappropriate content